Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill

Novo Nordisk said it will cut the U.S. price of its injectable Wegovy to $349/month from $499 and make first-time doses of Wegovy and Ozempic available for $149/month to Medicare, Medicaid and cash-paying patients via the government-backed TrumpRx platform and commercial partners, while pledging to “go all in” on an upcoming oral Wegovy pill awaiting a U.S. regulatory decision by year-end and asserting it has sufficient pill supply to avoid prior shortages. The aggressive pricing and commercial shift are designed to reclaim market share from Eli Lilly and lower-cost copycats as U.S. sales momentum slows—Novo expects fourth-quarter sales to fall about 4% after earlier growth—but the strategy raises execution and margin risk even as the company repositions its board to add consumer/OTC expertise.

Analysis

Novo Nordisk announced a U.S. list-price cut for injectable Wegovy from $499 to $349 per month for cash-paying patients and introduced first-time doses of Wegovy and Ozempic at $149 per month via the TrumpRx platform and commercial partners including GoodRx, WeightWatchers and Costco. CEO Mike Doustdar said the company will “go all in” on an oral Wegovy pill pending a U.S. regulatory decision by year-end and asserted the company now has sufficient pill supply to avoid the distribution shortfalls experienced during the 2021 launch.

The move is explicitly aimed at reclaiming share from rival Eli Lilly and lower-cost pharmacy/telehealth copies; Novo reported sales growth of 18% in the first quarter but has seen growth slow and now expects fourth-quarter sales to decline about 4% based on management's calculation. Management is also adding over-the-counter expertise to the board to respond to more consumer-like behavior among weight-loss drug users, while market signals show mildly negative sentiment toward Novo (sentiment_score -0.3) and a moderate market impact score (0.5).

The immediate trade-off is lower price realization to drive volume, creating margin and execution risk: Bellevue’s Paul Major flags the uncertainty that lower prices will be offset by incremental volume, and Novo’s strategy depends on timely FDA approval, effective oral launch execution and re-capturing lost U.S. demand. Investors should therefore watch month-over-month prescription uptake, gross-margin trends and patient acquisition costs as leading indicators of whether the pricing strategy restores growth or amplifies margin pressure.

Key Decisions for Investors

• Trim or neutralize NVO positions until clarity on Q4 sales reports and early uptake metrics confirm a volume offset to the price cuts.
• Monitor the FDA decision on the oral Wegovy by year-end and initial prescription and adherence data; consider selectively re-accumulating NVO on clear evidence of durable demand and controlled margin erosion.
• Consider increasing exposure to Eli Lilly (LLY) as a potential beneficiary if Novo’s price cuts and execution missteps fail to halt share loss, watching Lilly’s pricing and distribution signals closely.
• Track leading indicators: monthly active prescriptions, gross-margin trends, discounting through TrumpRx/GoodRx/Costco, and any renewed supply constraints; use those to time position adjustments.